Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 35 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Enzalutamide (Xtandi) for non-metastatic prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2017	View \| Download
Degarelix acetate prior to or with radiotherapy for prostate cancer	Degarelix acetate , Radiotherapy	Prostate cancer	Male Reproductive Cancer	2023	View \| Download
Darolutamide with androgen deprivation therapy for metastatic hormone sensitive prostate cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa)	Prostate cancer	Male Reproductive Cancer	2024	View \| Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous)	Prostate cancer	Male Reproductive Cancer	2021	View \| Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa)	Prostate cancer	Male Reproductive Cancer	2018	View \| Download
Capivasertib with abiraterone acetate for treating metastatic PTEN deficient hormone-sensitive prostate cancer	Abiraterone acetate (Zytiga; Yonsa) , Capivasertib	Prostate cancer	Male Reproductive Cancer	2024	View \| Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Apalutamide with primary radiation therapy for treating high-risk, localised or locally advanced prostate cancer	Apalutamide (Erleada; ARN-509) , Primary radiation therapy	Prostate cancer	Male Reproductive Cancer	2022	View \| Download